Abstract:Background: EGFR mutation is a strong predictor of efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) therapy in advanced non-small cell lung cancer (NSCLC). However, around 20-30 % of EGFR-mutated cases showed no response to EGFR-TKIs, suggesting that other determinants beyond EGFR mutation likely exist. This study analyzed the role of microRNAs (miRNAs) in primary resistance to EGFR-TKIs in advanced NSCLC patients with EGFR mutation.Methods: Training group: 20 advanced NSCLC patients with EGFR 19 deletion treated with first-line EGFR-TKIs were enrolled; half of them had dramatic responses while the other half had primary resistance. Matched plasma samples were collected for miRNA profiling using TaqMan low-density array (TLDA). Bioinformatics analyses were used to identify related miRNAs possibly accounted for resistance. Testing group: Quantitative reverse transcriptase PCR (qRT-PCR) was employed to detect the level of miRNA with significant differential expression in the training set. Validation group: Another cohort with EGFR 19 deletion mutations, who had dramatically different responses to EGFR-TKI, was used to validate the difference of miRNA expression between the sensitive and resistant groups using RT-PCR.Results: Training group: 153 miRNAs were found to be differentially expressed between the sensitive and resistant groups. Potential target genes were predicted with a target scan database. Twelve differentially expressed miRNAs were selected for the analysis because of their known roles in tumorigenesis of lung cancer, resistance to drugs, and regulation of EGFR pathway. Training group: three out of the 12 miRNAs (miR-21, AmiR-27a, and miR-218) were verified to have significantly higher expression (PmiR-21 = 0.004, PmiR-27a = 0.009, PmiR-218 = 0.041, respectively) in the resistant group compared to the sensitive group. Validation group: The expression levels of these three miRNAs were validated to be significantly different (P = 0.011, 0.011, 0.026, respectively) in the validation cohort (n = 34).Conclusions: Higher expression levels of miR-21, AmiR-27a, and miR-218 detected in this study suggest potential roles of these miRNAs in primary resistance to EGFR-TKI in advanced NSCLC patients with EGFR exon 19 deletion mutations. These findings need to be further confirmed in a study with a larger sample size.

Mir-200C Overexpression is Associated with Better Efficacy of EGFR-TKIs in Non-Small Cell Lung Cancer Patients with EGFR Wild-Type.

Mir-21 Overexpression Is Associated With Acquired Resistance Of Egfr-Tki In Non-Small Cell Lung Cancer

Association of Mirna Expression and EGFR Mutation Status in Lung Adenocarcinomas.

Epithelial Phenotype As a Predictive Marker for Response to EGFR-TKIs in Non-Small Cell Lung Cancer Patients with Wild-Type EGFR.

Association of Epithelial to Mesenchymal Transition with Efficacy of Egfr-Tkis in Non-Small Cell Lung Cancer Patients with Egfr Wild Type

microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation

MiRNA-200a Sensitizes Non-Small-cell Lung Cancer to EGFR-TKIs by Targeting FOXC1

Association of EGFR Exon 19 Deletion and Mirna Expression in Lung Adenocarcinomas.

Mir-223 Enhances the Sensitivity of Non-Small Cell Lung Cancer Cells to Erlotinib by Targeting the Insulin-Like Growth Factor-1 Receptor.

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Progress on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor for Treatment of Advanced Non-Small Cell Lung Cancer

Microarray Expression Profile of Long Non-Coding Rnas in Egfr-Tkis Resistance of Human Non-Small Cell Lung Cancer

Mir‐200c/bmi1 Axis and Epithelial–mesenchymal Transition Contribute to Acquired Resistance to BRAF Inhibitor Treatment

MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines

HER2 Overexpression Reverses the Relative Resistance of EGFR-mutant H1975 Cell Line to Gefitinib.

Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer

Increased MIR31HG Lncrna Expression Increases Gefitinib Resistance in Non-Small Cell Lung Cancer Cell Lines Through the EGFR/PI3K/AKT Signaling Pathway

MicroRNAs and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors Sensitivity in Non-Small Cell Lung Cancer

The Mir‑625‑3p/axl Axis Induces Non‑t790m Acquired Resistance to EGFR‑TKI Via Activation of the TGF‑β/Smad Pathway and EMT in EGFR‑mutant Non‑small Cell Lung Cancer.

Identification of Plasma Microrna Profiles for Primary Resistance to EGFR-TKIs in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Activating Mutation.

Epigenetic Silencing of Mir-483-3p Promotes Acquired Gefitinib Resistance and EMT in EGFR-mutant NSCLC by Targeting Integrin Β3